Russian Scientists Conduct Autopsy on 44,000-year-old Permafrost Wolf Carcass

Scientists perform an autopsy of an ancient wolf, frozen in permafrost for more than 44,000 years and found by locals in Yakutia, at the laboratory of the North-Eastern Federal University in Yakutsk, Russia June 18, 2024. Michil Yakovlev/North-Eastern Federal University/Handout via REUTERS
Scientists perform an autopsy of an ancient wolf, frozen in permafrost for more than 44,000 years and found by locals in Yakutia, at the laboratory of the North-Eastern Federal University in Yakutsk, Russia June 18, 2024. Michil Yakovlev/North-Eastern Federal University/Handout via REUTERS
TT

Russian Scientists Conduct Autopsy on 44,000-year-old Permafrost Wolf Carcass

Scientists perform an autopsy of an ancient wolf, frozen in permafrost for more than 44,000 years and found by locals in Yakutia, at the laboratory of the North-Eastern Federal University in Yakutsk, Russia June 18, 2024. Michil Yakovlev/North-Eastern Federal University/Handout via REUTERS
Scientists perform an autopsy of an ancient wolf, frozen in permafrost for more than 44,000 years and found by locals in Yakutia, at the laboratory of the North-Eastern Federal University in Yakutsk, Russia June 18, 2024. Michil Yakovlev/North-Eastern Federal University/Handout via REUTERS

In Russia's far northeastern Yakutia region, local scientists are performing an autopsy on a wolf frozen in permafrost for around 44,000 years, a find they said was the first of its kind.
Found by chance by locals in Yakutia's Abyyskiy district in 2021, the wolf's body is only now being properly examined by scientists, Reuters reported Friday.
"This is the world's first discovery of a late Pleistocene predator," said Albert Protopopov, head of the department for the study of mammoth fauna at the Yakutia Academy of Sciences.
"Its age is about 44,000 years, and there have never been such finds before," he said.
Sandwiched between the Arctic Ocean and in Russia's Arctic far east, Yakutia is a vast region of swamps and forests around the size of Texas, around 95% of which is covered in permafrost.
Winter temperatures in the region have been known to drop to as low as minus 64 degrees Celsius (-83.2°F)
"Usually, it's the herbivorous animals that die, get stuck in swamps, freeze and reach us as a whole. This is the first time when a large carnivore has been found," said Protopopov.
While it's not unusual to find millennia-old animal carcasses buried deep in permafrost, which is slowly melting due to climate change, the wolf is special, Protopopov said.
"It was a very active predator, one of the larger ones. Slightly smaller than cave lions and bears, but a very active, mobile predator, and it was also a scavenger," he added.
For Artyom Nedoluzhko, development director of the paleogenetics laboratory at the European University of St. Petersburg, the wolf's remains offer a rare insight into the Yakutia of 44,000 years ago.
"The main goal is to understand what this wolf fed on, who it was, and how it relates to those ancient wolves that inhabited the northeastern part of Eurasia," he said.



Axsome's Alzheimer's-related Drug Shows Mixed Results in Late-stage Studies

The human brain. Illustration: AFP
The human brain. Illustration: AFP
TT

Axsome's Alzheimer's-related Drug Shows Mixed Results in Late-stage Studies

The human brain. Illustration: AFP
The human brain. Illustration: AFP

Axsome Therapeutics said on Monday its experimental drug to treat agitation related to Alzheimer's disease succeeded in one of the two late-stage studies and failed to meet the main goal of the second trial.

Shares of the drug developer, which was testing the treatment, AXS-05, dropped 12% in premarket trading, Reuters reported.

The agitation is a symptom that causes emotional distress as well as verbal and physical aggressiveness.

The treatment significantly delayed the time to relapse in agitation as measured on a disease severity scale in one study, but did not demonstrate statistical significance in delaying agitation in another late-stage trial.

AXS-05 was safe and well tolerated in both the studies, the company said.